Metraipolis › archive › dc_ff920a9f78db

The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis — Europe PMC PMID:41450584

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41450584
DOI
10.3389/fendo.2025.1646956
License (as archived)
solo-consultazione
Archived
2026-11-07T17:54:11.945Z
SHA-256 of the archived text
98e176f0f05d97d9e73adafcb20ac794407b8c194259c751caa1b7af0e894fb9
Stable URL of this page
https://metraipolis.com/documento/dc_ff920a9f78db

How to cite

The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis — Europe PMC PMID:41450584 — Europe PMC (en), https://europepmc.org/article/MED/41450584 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ff920a9f78db (Metraipolis archive dc_ff920a9f78db, sha256 98e176f0f05d97d9e73adafcb20ac794407b8c194259c751caa1b7af0e894fb9)
BibTeX
@misc{dcff920a9f78db,
  title = {The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis — Europe PMC PMID:41450584},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41450584},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ff920a9f78db; sha256 98e176f0f05d97d9e73adafcb20ac794407b8c194259c751caa1b7af0e894fb9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41450584. Agents can read the archived copy with the MCP tool read_document.